Harrow, Inc. Amortization of Debt Discount (Premium)
Harrow, Inc. (HROW) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2021-03-08
- Harrow, Inc. amortization of debt discount (premium) for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Harrow, Inc. amortization of debt discount (premium) for the quarter ending 2019-09-30 was $1.00K, a 99.24% decline year-over-year.
- Harrow, Inc. amortization of debt discount (premium) for the quarter ending 2019-06-30 was $6.00K, a 95.38% decline year-over-year.
- Harrow, Inc. amortization of debt discount (premium) for the quarter ending 2019-03-31 was $10.00K, a 92.19% decline year-over-year.
- Harrow, Inc. amortization of debt discount (premium) for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Harrow, Inc. amortization of debt discount (premium) for fiscal 2019 was $17.00K, a 96.73% decline from fiscal 2018.
- Harrow, Inc. amortization of debt discount (premium) for fiscal 2018 was $520.00K, a 35.88% decline from fiscal 2017.
- Harrow, Inc. amortization of debt discount (premium) for fiscal 2017 was $811.00K, a 16.39% decline from fiscal 2016.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month | Amortization of Debt Discount (Premium) 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-08 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $1.00K derived: sum of 2 quarters · filed 2021-03-08 | $7.00K derived: sum of 3 quarters · filed 2021-03-08 | $17.00K 10-K · filed 2021-03-08 | |
| 2019-09-30 | $1.00K 10-Q · filed 2019-11-13 | $7.00K derived: sum of 2 quarters · filed 2019-11-13 | $17.00K 10-Q · filed 2019-11-13 | $148.00K derived: sum of 4 quarters · filed 2019-11-13 | |
| 2019-06-30 | $6.00K 10-Q · filed 2019-08-14 | $13.00K 10-Q · filed 2019-08-14 | $147.00K derived: sum of 3 quarters · filed 2019-08-14 | $278.00K derived: sum of 4 quarters · filed 2019-08-14 | |
| 2019-03-31 | $10.00K 10-Q · filed 2019-05-09 | $141.00K derived: sum of 2 quarters · filed 2019-05-09 | $272.00K derived: sum of 3 quarters · filed 2019-05-09 | $402.00K derived: sum of 4 quarters · filed 2019-05-09 | |
| 2018-12-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $262.00K derived: sum of 2 quarters · filed 2019-03-12 | $392.00K derived: sum of 3 quarters · filed 2019-03-12 | $520.00K 10-K · filed 2019-03-12 | |
| 2018-09-30 | $131.00K 10-Q · filed 2018-11-13 | $261.00K derived: sum of 2 quarters · filed 2018-11-13 | $389.00K 10-Q · filed 2018-11-13 | $388.00K derived: sum of 4 quarters · filed 2019-03-12 | |
| 2018-06-30 | $130.00K 10-Q · filed 2018-08-06 | $258.00K 10-Q · filed 2018-08-06 | $257.00K derived: sum of 3 quarters · filed 2019-03-12 | $398.00K derived: sum of 4 quarters · filed 2019-03-12 | |
| 2018-03-31 | $128.00K 10-Q · filed 2018-05-15 | $127.00K derived: sum of 2 quarters · filed 2019-03-12 | $268.00K derived: sum of 3 quarters · filed 2019-03-12 | $564.00K derived: sum of 4 quarters · filed 2019-03-12 | |
| 2017-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $140.00K derived: sum of 2 quarters · filed 2019-03-12 | $436.00K derived: sum of 3 quarters · filed 2019-03-12 | $811.00K 10-K · filed 2019-03-12 | $978.00K 10-K · filed 2018-03-08 |
| 2017-09-30 | $141.00K 10-Q · filed 2017-11-14 | $437.00K derived: sum of 2 quarters · filed 2017-11-14 | $812.00K 10-Q · filed 2017-11-14 | $914.00K derived: sum of 4 quarters · filed 2018-03-08 | |
| 2017-06-30 | $296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $632.00K 10-Q · filed 2017-08-10 | $773.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.04M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2017-03-31 | $336.00K 10-Q · filed 2017-05-10 | $477.00K derived: sum of 2 quarters · filed 2018-03-08 | $742.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.01M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $406.00K derived: sum of 2 quarters · filed 2018-03-08 | $670.00K derived: sum of 3 quarters · filed 2018-03-08 | $970.00K 10-K · filed 2018-03-08 | |
| 2016-09-30 | $265.00K 10-Q · filed 2017-11-14 | $529.00K derived: sum of 2 quarters · filed 2017-11-14 | $829.00K 10-Q · filed 2017-11-14 | $897.00K derived: sum of 4 quarters · filed 2017-11-14 | |
| 2016-06-30 | $264.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $526.00K 10-Q · filed 2017-08-10 | $632.00K derived: sum of 3 quarters · filed 2017-08-10 | $702.00K derived: sum of 4 quarters · filed 2017-08-10 | |
| 2016-03-31 | $262.00K 10-Q · filed 2017-05-10 | $368.00K derived: sum of 2 quarters · filed 2017-05-10 | $438.00K derived: sum of 3 quarters · filed 2017-05-10 | $508.00K derived: sum of 4 quarters · filed 2017-05-10 | |
| 2015-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $176.00K derived: sum of 2 quarters · filed 2017-03-21 | $246.00K derived: sum of 3 quarters · filed 2017-03-21 | $281.00K 10-K · filed 2017-03-21 | |
| 2015-09-30 | $70.00K 10-Q · filed 2015-11-12 | $140.00K derived: sum of 2 quarters · filed 2015-11-12 | $175.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $70.00K 10-Q · filed 2015-08-12 | $70.00K 10-Q · filed 2016-08-15 | |||
| 2007-12-31 | $1.53M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |